BMRN BioMarin Pharmaceutical Inc.

88.62
-4.92  -5%
Previous Close 93.54
Open 93.40
Price To book 5.56
Market Cap 15532278607
Shares 175,268,321
Volume 3,816,247
Short Ratio 6.27
Av. Daily Volume 1,295,441

SEC filingsSee all SEC filings

  1. 8-K - Current report 171117929
  2. 8-K - Current report 171025405
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171018871
  4. FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses 171018802
  5. 305B2 - Filing [Trust Indenture Act] 171013138

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 July 11, 2017. 97% reduction in Annualized Bleed Rate (ABR). Phase 3 trials to be initiated 4Q 2017.
BMN 270
Hemophilia A
Phase 3 trial initiation announced December 12, 2016.
Vosoritide
Achondroplasia
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. PDUFA action date is February 28, 2018 under priority review. However, company noted September 14, 2017 that a 3-month delay is likely. No Adcom expected.
Pegvaliase
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)

Latest News

  1. BioMarin Pharmaceutical: Cramer's Top Takeaways
  2. BioMarin is 'close as can get' to a hemophilia cure, CEO ...
  3. Have Investors Already Priced In BioMarin Pharmaceutical Inc’s (BMRN) Growth?
  4. BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
  5. See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
  6. BioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell
  7. How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs
  8. BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
  9. BioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, October 26 at 4:30 p.m. ET
  10. Analysts’ Recommendations for Biogen in October 2017
  11. Alexion on the Street: Analyst Recommendations in October
  12. BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
  13. ETFs with exposure to BioMarin Pharmaceutical, Inc. : September 27, 2017
  14. Here's Why Sarepta Stock is Up More Than 60% So Far in 2017
  15. Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
  16. BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA